Page last updated: 2024-10-30

ketotifen and 48,XXYY Syndrome

ketotifen has been researched along with 48,XXYY Syndrome in 1 studies

Ketotifen: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis.
ketotifen : An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Willems, M1
Seβenhausen, P1
Gies, I1
Vloeberghs, V1
Tournaye, H1
Van Saen, D1
Goossens, E1

Other Studies

1 other study available for ketotifen and 48,XXYY Syndrome

ArticleYear
Intratesticular xenografting of Klinefelter pre-pubertal testis tissue as potential model to study testicular fibrosis.
    Reproductive biomedicine online, 2022, Volume: 44, Issue:5

    Topics: Animals; Female; Fibrosis; Humans; Ketotifen; Klinefelter Syndrome; Longitudinal Studies; Male; Mice

2022